A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease

Million Veteran Program

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Analyzing 12,361 all-cause cirrhosis cases and 790,095 controls from eight cohorts, we identify a common missense variant in the Mitochondrial Amidoxime Reducing Component 1 gene (MARC1 p.A165T) that associates with protection from all-cause cirrhosis (OR 0.91, p = 2.3∗10-11). This same variant also associates with lower levels of hepatic fat on computed tomographic imaging and lower odds of physician-diagnosed fatty liver as well as lower blood levels of alanine transaminase (-0.025 SD, 3.7∗10-43), alkaline phosphatase (-0.025 SD, 1.2∗10-37), total cholesterol (-0.030 SD, p = 1.9∗10-36) and LDL cholesterol (-0.027 SD, p = 5.1∗10-30) levels. We identified a series of additional MARC1 alleles (lowfrequency missense p.M187K and rare protein-truncating p.R200Ter) that also associated with lower cholesterol levels, liver enzyme levels and reduced risk of cirrhosis (0 cirrhosis cases for 238 R200Ter carriers versus 17,046 cases of cirrhosis among 759,027 non-carriers, p = 0.04) suggesting that deficiency of the MARC1 enzyme may lower blood cholesterol levels and protect against cirrhosis.

Original languageEnglish
Article numbere1008629
JournalPLoS Genetics
Volume16
Issue number4
DOIs
StatePublished - Apr 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease'. Together they form a unique fingerprint.

Cite this